Biological markers in Alzheimer's disease.
Biomarkers are required to improve our diagnostic sensitivity and specificity and to monitor the biological activity of the Alzheimer's disease (AD) in terms of the burden of neural involvement and the tempo of disease progression. Biomarkers will initially supplement our more traditional neuropsychological and imaging markers but may eventually evolve into useful surrogate endpoints in AD research. These markers may also provide important mechanistic clues to the pharmacological action of anti-dementia compounds. At this point, the combination of elevated cerebrospinal fluid phosphorylated TAU (CSF p-TAU) proteins and low CSF ABeta(1-42) are the only biomarkers with the sensitivity and specificity to serve as useful diagnostic biomarkers capable of distinguishing AD from other dementias in the early stages. Advances in non CSF tests is urgently required. Markers assessing the progression of disease do not necessarily require the same high disease specificity as diagnostic markers, but need to be sensitive to changes in disease state. At present, candidate markers fall under four main biological rationales: (1) Specific markers of AD neuropathology; (2) Non-specific markers of neural degeneration; (3) Markers of oxidative stress; (4) Markers of neural inflammation. It is foreseeable that a panel of such markers might prove advantageous. It will be important to develop "non-invasive" markers utilizing readily obtainable tissue samples such as serum or urine to monitor disease progression (or hopefully regression). Repeated sampling would allow for comparison with traditional neuropsychological and imaging measures. The assays themselves will need to be reproducible, reliable and relatively inexpensive. Unfortunately, these biomarkers are in the formative stages of testing and results at present are inconclusive. To facilitate biomarker development in the future it would be highly advantageous to begin to collect and store biological specimens as an adjunct to current research in AD.
Bailey
Peter
P
Department of Medicine, Dalhousie University, Saint John Regional Hospital, Saint John, New Brunswick, Canada.
D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000175:diagnosis* / Q000503:physiopathology*; D016229:Amyloid beta-Peptides / Q000032:analysis / Q000134:cerebrospinal fluid; D015415:Biomarkers / Q000032:analysis / Q000134:cerebrospinal fluid; D001921:Brain / Q000378:metabolism / Q000503:physiopathology*; D003937:Diagnosis, Differential; D004660:Encephalitis / Q000175:diagnosis* / Q000378:metabolism / Q000503:physiopathology*; D006801:Humans; D009410:Nerve Degeneration / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000503:physiopathology; D018384:Oxidative Stress / Q000502:physiology; D010446:Peptide Fragments / Q000032:analysis / Q000134:cerebrospinal fluid; D016875:tau Proteins / Q000032:analysis / Q000134:cerebrospinal fluid
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins